Liquidia (LQDA) Cash & Equivalents Growth (1y) (2020 - 2026)
Powered by 
Analysis
Liquidia (LQDA) Cash & Equivalents Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.53 Bn | 625.77 Bn | 17.26 Bn | 9.93% |
| 2 | AbbVie | 442.27 Bn | 435.70 Bn | 12.70 Bn | 1.58% |
| 3 | Merck | 366.81 Bn | 359.67 Bn | 12.21 Bn | -14.46% |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | 14.42% |
| 5 | Pfizer | 159.37 Bn | 147.67 Bn | 10.94 Bn | -40.42% |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn | -57.55% |
| 7 | Revolution Medicines | 44.12 Bn | 44.12 Bn | - | - |
| 8 | Incyte | 25.49 Bn | 20.95 Bn | 1.57 Bn | 103.71% |
| 9 | United Therapeutics | 21.55 Bn | 18.89 Bn | 683.80 Mn | 13.19% |
| 10 | Liquidia | 6.09 Bn | 5.80 Bn | 160.92 Mn | 63.87% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 63.87% |
| Mar 31, 2026 | 31.24% |
| Dec 31, 2025 | 8.05% |
| Sep 30, 2025 | -22.94% |
| Jun 30, 2025 | 30.30% |
| Mar 31, 2025 | 7.54% |
| Dec 31, 2024 | 110.90% |
| Sep 30, 2024 | 168.11% |
| Jun 30, 2024 | 50.91% |
| Mar 31, 2024 | 67.20% |
| Dec 31, 2023 | -10.30% |
| Sep 30, 2023 | -22.47% |
| Jun 30, 2023 | -15.07% |
| Mar 31, 2023 | 63.34% |
| Dec 31, 2022 | 62.25% |
| Sep 30, 2022 | 53.39% |
| Jun 30, 2022 | 52.93% |
| Mar 31, 2022 | 7.76% |
| Dec 31, 2021 | -11.98% |
| Dec 31, 2020 | 17.06% |